We prospectively assigned 289 consecutive children with acute lymphoblastic leukemia to receive one of two treatment programs on the basis of the presence or absence of certain risk factors at the time of diagnosis. Patients at high risk (62 percent of the total) had one or more of the following risk factors: age below two or above nine years, a white-cell count of 20,000 per cubic millimeter or more, the presence of T-cell immunologic markers, radiologic evidence of a mediastinal mass, and involvement of the central nervous system. Patients in both the standard-risk and high-risk groups were treated for two years, receiving intensive remission-induction therapy, central nervous system prophylaxis, weekly administration of high-dose asparaginase, and multiple-drug continuation therapy (which in the high-risk group included doxorubicin and a larger dose of prednisone). At a median follow-up of 35 months, the mean (+/- SE) event-free survival rates at four years among the patients in the standard-risk and high-risk groups were 86 +/- 4 percent and 71 +/- 4 percent, respectively (P = 0.003), for a total event-free survival of 77 +/- 3 percent. Within the high-risk group, the white-cell count at diagnosis and the sex of the patient were not significant prognostic indicators, but age below 12 months at diagnosis was associated with a very poor outcome. As compared with previous methods, this treatment program using four-drug induction and intensive asparaginase therapy has resulted in improved event-free survival in children with acute lymphoblastic leukemia.
This article has been cited by other articles:
Oudot, C., Auclerc, M.-F., Levy, V., Porcher, R., Piguet, C., Perel, Y., Gandemer, V., Debre, M., Vermylen, C., Pautard, B., Berger, C., Schmitt, C., Leblanc, T., Cayuela, J.-M., Socie, G., Michel, G., Leverger, G., Baruchel, A.
(2008). Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study. JCO
26: 1496-1503
[Abstract][Full Text]
Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., Pazdur, R.
(2007). FDA Drug Approval Summary: Pegaspargase (Oncaspar(R)) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL). The Oncologist
12: 991-998
[Abstract][Full Text]
Douer, D., Yampolsky, H., Cohen, L. J., Watkins, K., Levine, A. M., Periclou, A. P., Avramis, V. I.
(2007). Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood
109: 2744-2750
[Abstract][Full Text]
Caruso, V., Iacoviello, L., Di Castelnuovo, A., Storti, S., Mariani, G., de Gaetano, G., Donati, M. B.
(2006). Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood
108: 2216-2222
[Abstract][Full Text]
Pession, A., Valsecchi, M. G., Masera, G., Kamps, W. A., Magyarosy, E., Rizzari, C., van Wering, E. R., Lo Nigro, L., van der Does, A., Locatelli, F., Basso, G., Arico, M.
(2005). Long-Term Results of a Randomized Trial on Extended Use of High Dose L-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia. JCO
23: 7161-7167
[Abstract][Full Text]
Goldberg, J. M., Silverman, L. B., Levy, D. E., Dalton, V. K., Gelber, R. D., Lehmann, L., Cohen, H. J., Sallan, S. E., Asselin, B. L.
(2003). Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience. JCO
21: 3616-3622
[Abstract][Full Text]
Schiffer, C. A.
(2003). Differences in Outcome in Adolescents With Acute Lymphoblastic Leukemia: A Consequence of Better Regimens? Better Doctors? Both?. JCO
21: 760-761
[Full Text]
Duval, M., Suciu, S., Ferster, A., Rialland, X., Nelken, B., Lutz, P., Benoit, Y., Robert, A., Manel, A.-M., Vilmer, E., Otten, J., Philippe, N.
(2002). Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer---Children's Leukemia Group phase 3 trial. Blood
99: 2734-2739
[Abstract][Full Text]
LeClerc, J. M., Billett, A. L., Gelber, R. D., Dalton, V., Tarbell, N., Lipton, J. M., Barr, R., Clavell, L. A., Asselin, B., Hurwitz, C., Schorin, M., Lipshultz, S. E., Declerck, L., Silverman, L. B., Cohen, H. J., Sallan, S. E.
(2002). Treatment of Childhood Acute Lymphoblastic Leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01. JCO
20: 237-246
[Abstract][Full Text]
Rizzari, C., Valsecchi, M.G., Arico, M., Conter, V., Testi, A., Barisone, E., Casale, F., Lo Nigro, L., Rondelli, R., Basso, G., Santoro, N., Masera, G.
(2001). Effect of Protracted High-Dose L-Asparaginase Given as a Second Exposure in a Berlin-Frankfurt-Munster-Based Treatment: Results of the Randomized 9102 Intermediate-Risk Childhood Acute Lymphoblastic Leukemia Study--A Report From the Associazione Italiana Ematologia Oncologia Pediatrica. JCO
19: 1297-1303
[Abstract][Full Text]
Silverman, L. B., Gelber, R. D., Dalton, V. K., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Arkin, S., Declerck, L., Cohen, H. J., Sallan, S. E.
(2001). Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood
97: 1211-1218
[Abstract][Full Text]
Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P., Buchanan, G. R.
(2000). Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood
96: 1709-1715
[Abstract][Full Text]
Woerden, N. L. R.-v., Pieters, R., Loonen, A. H., Hubeek, I., van Drunen, E., Beverloo, H. B., Slater, R. M., Harbott, J., Seyfarth, J., van Wering, E. R., Hahlen, K., Schmiegelow, K., Janka-Schaub, G. E., Veerman, A. J. P.
(2000). TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood
96: 1094-1099
[Abstract][Full Text]
Heerema, N. A., Sather, H. N., Sensel, M. G., Zhang, T., Hutchinson, R. J., Nachman, J. B., Lange, B. J., Steinherz, P. G., Bostrom, B. C., Reaman, G. H., Gaynon, P. S., Uckun, F. M.
(2000). Prognostic Impact of Trisomies of Chromosomes 10, 17, and 5 Among Children With Acute Lymphoblastic Leukemia and High Hyperdiploidy (> 50 Chromosomes). JCO
18: 1876-1887
[Abstract][Full Text]
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., Ha, C. S., Keating, M. J., Murphy, S., Freireich, E. J.
(2000). Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. JCO
18: 547-547
[Abstract][Full Text]
Kudoh, T., Otoi, H., Suzuki, N., Oda, T., Katoh, S., Akiba, H., Hareyama, M., Chiba, S.
(2000). Simultaneous Development of a Pineal Tumor and an Intradural Spinal Mass During Remission of Acute Lymphocytic Leukemia. Jpn J Clin Oncol
30: 105-108
[Abstract][Full Text]
Nowak-Gottl, U., Wermes, C., Junker, R., Koch, H.-G., Schobess, R., Fleischhack, G., Schwabe, D., Ehrenforth, S.
(1999). Prospective Evaluation of the Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors. Blood
93: 1595-1599
[Abstract][Full Text]
Loh, M. L., Silverman, L. B., Young, M. L., Neuberg, D., Golub, T. R., Sallan, S. E., Gilliland, D. G.
(1998). Incidence of TEL/AML1 Fusion in Children With Relapsed Acute Lymphoblastic Leukemia. Blood
92: 4792-4797
[Abstract][Full Text]
Nachman, J. B., Sather, H. N., Sensel, M. G., Trigg, M. E., Cherlow, J. M., Lukens, J. N., Wolff, L., Uckun, F. M., Gaynon, P. S.
(1998). Augmented Post-Induction Therapy for Children with High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy. NEJM
338: 1663-1671
[Abstract][Full Text]
Uckun, F. M., Sensel, M. G., Sun, L., Steinherz, P. G., Trigg, M. E., Heerema, N. A., Sather, H. N., Reaman, G. H., Gaynon, P. S.
(1998). Biology and Treatment of Childhood T-Lineage Acute Lymphoblastic Leukemia. Blood
91: 735-746
[Full Text]
Parsons, S. K., Skapek, S. X., Neufeld, E. J., Kuhlman, C., Young, M. L., Donnelly, M., Brunzell, J. D., Otvos, J. D., Sallan, S. E., Rifai, N.
(1997). Asparaginase-Associated Lipid Abnormalities in Children With Acute Lymphoblastic Leukemia. Blood
89: 1886-1895
[Abstract][Full Text]
Rivera, G. K., Pinkel, D., Simone, J. V., Hancock, M. L., Crist, W. M.
(1993). Treatment of Acute Lymphoblastic Leukemia -- 30 Years' Experience at St. Jude Children's Research Hospital. NEJM
329: 1289-1295
[Abstract][Full Text]
Mahmoud, H. H., Rivera, G. K., Hancock, M. L., Krance, R. A., Kun, L. E., Behm, F. G., Ribeiro, R. C., Sandlund, J. T., Crist, W. M., Pui, C.-H.
(1993). Low Leukocyte Counts with Blast Cells in Cerebrospinal Fluid of Children with Newly Diagnosed Acute Lymphoblastic Leukemia. NEJM
329: 314-319
[Abstract][Full Text]
Hammond, E.
(1988). Anaphylactic Reactions to Chemotherapeutic Agents. Journal of Pediatric Oncology Nursing
5: 16-19
